SSTR2 and neuroendocrine neoplasm: In neuroendocrine tumors (NETs), SSTR2 expression is imaged with 68Ga-DOTA-peptide radioconjugates and therapeutically exploited by 177Lu- or 90Y-DOTA-peptide radioconjugates and SSTR2 agonists such as the octreotide octapeptide5,6.